Karyopharm Therapeutics Inc (KPTI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.79+1.13%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · KPTI
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||
| Revenues | 146.6 | 146.1 | 145.2 | 146.0 | 157.1 | 209.8 | 108.1 | 40.9 | 30.3 | — | 0.2 | 0.3 | 0.2 | 0.4 |
| Total Revenues | — | — | — | — | — | — | — | — | — | — | 0.2 | 0.3 | 0.2 | 0.4 |
| Operating Expenses & Income | ||||||||||||||
| Selling, General & Admin | 102.0 | 105.2 | 115.4 | 131.9 | 145.4 | 143.8 | 126.4 | 105.4 | — | — | — | — | — | — |
| R&D Expenses | 121.0 | 125.6 | 143.2 | 138.8 | 148.7 | 160.8 | 150.8 | 122.3 | 161.4 | 107.3 | 86.9 | 97.7 | 60.1 | 28.5 |
| Operating Income | (82.4) | (90.7) | (119.4) | (129.5) | (142.2) | (98.3) | (171.9) | (189.3) | (179.9) | (130.5) | (110.7) | (119.1) | (75.8) | (34.0) |
| Earnings from Continuing Operations | ||||||||||||||
| Interest Expense | — | 45.8 | 37.4 | 23.8 | 25.0 | 26.0 | 27.1 | 15.6 | 2.5 | — | 0.0 | 0.0 | 0.0 | — |
| Interest & Investment Income | 2.4 | 2.8 | 7.4 | 10.9 | 2.4 | 0.6 | 2.8 | 5.4 | 4.0 | 1.7 | 1.3 | 0.9 | 0.1 | 0.0 |
| Net Interest Expenses | — | — | — | 12.9 | 22.6 | 25.5 | 24.3 | 10.2 | (1.5) | — | (1.3) | (0.9) | (0.1) | — |
| Other Non-Operating Income / Expenses | (142.4) | (105.3) | 43.1 | (13.2) | (22.7) | (25.5) | (24.1) | (10.3) | 1.5 | 1.6 | 1.3 | 0.9 | — | — |
| EBT, Incl. Unusual Items | (224.8) | (196.0) | (76.4) | (142.8) | (164.9) | (123.8) | (196.0) | (199.6) | (178.4) | (128.9) | (109.4) | — | — | — |
| Income Tax Expense | — | 0.0 | 0.1 | 0.3 | 0.4 | 0.3 | 0.3 | 0.0 | 0.0 | 0.1 | 0.1 | (118.1) | (75.8) | (33.9) |
| Net Income | ||||||||||||||
| Net Income | (224.7) | (196.0) | (76.4) | (143.1) | (165.3) | (124.1) | (196.3) | (199.6) | (178.4) | (129.0) | (109.6) | (118.2) | (75.8) | (33.9) |
| Per Share | ||||||||||||||
| Basic EPS | (7,766.25) | (17.93) | (0.63) | (18.79) | (2.02) | (1.65) | (2.72) | — | — | — | — | — | — | — |
| Diluted EPS | (7,766.25) | (17.93) | (0.93) | (18.79) | (2.02) | (1.65) | (2.72) | — | — | — | — | — | — | — |
| Revenue per Share | 5,066.73 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 0.0 | 0.0 | 0.1 | 0.0 | 0.1 | 75.2 | 72.0 | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 0.0 | 0.0 | 0.1 | 0.0 | 0.1 | 75.2 | 72.0 | — | — | — | — | — | — | — |
| Supplemental | ||||||||||||||
| EBITDA | — | — | — | — | — | — | — | (188.3) | (179.1) | (129.8) | (110.0) | (118.4) | (75.5) | (33.8) |
| EBIT | (82.4) | (90.7) | (119.4) | (129.5) | (142.2) | (98.3) | (171.9) | (189.3) | (179.9) | (130.5) | (110.7) | (119.1) | (75.8) | (34.0) |
| Effective Tax Rate | — | — | — | -0.2% | -0.2% | -0.2% | -0.2% | -0.0% | -0.0% | -0.0% | -0.1% | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.